about
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactationDecreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohortHigh levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort.Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus.2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies.International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies.Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case studyPentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritisCertolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis.The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical RemissionExpression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis.Resistin in idiopathic inflammatory myopathies.Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort studyDevelopment of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseasesMicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritisEfficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders.A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.Treatment-resistant inflammatory myopathy.Clinical trials roundup in idiopathic inflammatory myopathies.European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.The role of resistin in inflammatory myopathies.Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations.
P50
Q26765038-74A6F7DD-BCB3-4581-85E7-EDAED90779FCQ30839061-3FB3319E-F552-44F5-9C6D-C8F8C7DA9B84Q30876263-8CA50F07-8C45-44E5-A416-7FB5C8F8B926Q34061733-3F6792D9-06F4-497D-BA8F-B7CCA0378C37Q34130671-1D1E844F-22D1-4AFA-BC96-B72C737F125AQ34237586-6B83B343-4CCC-4496-A945-8C75E6FA5050Q34440026-3EF16A9B-2EE2-4E26-9C89-613A4A149CDAQ34490287-47A985F0-77EF-4AB4-A09E-8E4A70904BCCQ34528042-F802A524-606D-4747-AD74-CA744B3E5A7CQ34560305-2AD03B3D-4534-4E49-855B-573CF3007E1EQ35179618-C5DDA65A-E694-46F2-AD1D-512CCE2F497DQ35554739-77D68A53-A106-4855-B95C-9B14C4FA0B82Q35617658-A3995AEA-85D6-4DD0-AD3D-9AAA5649DCBBQ35752908-2AADAF76-1837-43DF-A9C6-53D62409349EQ35882730-77636C8A-E18C-418A-A48C-AE77134EA7E4Q35962863-CDFB8B86-64E7-4423-81F7-6D9F049F2D6AQ36020198-33F0D252-68F9-40A0-977C-1FF4C905C9AFQ36041246-622C9665-EB3A-48C7-A34A-DE34CA1A8412Q36045392-507509EF-7750-48FD-812B-DE63EB3B6BA0Q36067062-6A9468DC-BAA6-425A-A26F-378A39AD91B2Q36084879-EEA3A475-7690-4A8B-88C9-518E03FD871EQ36183786-308A8CC6-90C4-46EB-A76C-47C50F027527Q36188496-A377CFC0-CE82-4D18-A848-FA5FF74B6961Q36205767-3133DD4D-0700-4BA8-9E7C-1A6599C5C5F7Q36245955-F4BE757A-98EA-4D7F-A7EB-9CABE16CF766Q36321563-696D98D2-10BC-4DB1-96D3-A948E937C21AQ36335887-EBA4BA9A-7CF5-4771-8921-DBD7493C0B3EQ36424500-EFE92987-1A98-43E3-A71A-700ABCC9EF82Q36588160-E1973282-77DD-4F4F-976A-B8EF8FEEF5C6Q36960767-1EC3DC59-B0AE-4039-AF0B-CE99F4D03C8DQ37172815-33B22377-9F3B-43F2-ACC2-D9201F2BE8EDQ37172820-A120B6B2-B3F3-4C07-B0A5-3B9185D916AAQ37601815-9A3F8C85-D260-4C2F-8182-0F77FC0BF3BFQ37604518-02547E9C-B24B-4C08-8C2A-62E53C946A85Q37763782-7EE71104-7055-49CB-9FEC-A517AE7F759DQ37934396-6BF45D3B-7F6F-4DAC-9682-96F3BB8D40A9Q37939700-60718E02-0A1C-4AC6-9FDE-4CB9353C39D8Q38021653-6E00CD7E-35F6-4231-B955-93DE050EC2BBQ38099557-7645F4DE-F155-4527-AF14-04337B50FDFFQ38208567-A24634C3-5159-405A-94E4-372970B446F2
P50
description
hulumtues
@sq
researcher
@en
revmatolog a imunolog
@cs
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jiří Vencovský
@ast
Jiří Vencovský
@cs
Jiří Vencovský
@en
Jiří Vencovský
@es
Jiří Vencovský
@nl
Jiří Vencovský
@sl
type
label
Jiří Vencovský
@ast
Jiří Vencovský
@cs
Jiří Vencovský
@en
Jiří Vencovský
@es
Jiří Vencovský
@nl
Jiří Vencovský
@sl
altLabel
Jiri Vencovsky
@en
Jiří Vencovský
@en
prefLabel
Jiří Vencovský
@ast
Jiří Vencovský
@cs
Jiří Vencovský
@en
Jiří Vencovský
@es
Jiří Vencovský
@nl
Jiří Vencovský
@sl
P106
P214
P1053
G-6094-2017
P1153
55941728700
P21
P214
P31
P3829
P496
0000-0002-0851-0713
P569
1953-11-16T00:00:00Z
P691
jo20000080529
P734
P7859
viaf-84117517